Verve Therapeutics
Verve Therapeutics raises $213M Series C at $1B valuation
Quick Facts
Verve Therapeutics: Series C Funding Round
Verve Therapeutics has successfully raised $213M in Series C funding, reaching a valuation of $1B.
Company Overview
Gene editing for heart disease
Funding Details
The Series C round was led by Foresite Capital, with participation from GV, F-Prime Capital, ARCH Venture Partners, Biomatics Capital.
Company Information
- Headquarters: 26 Landsdowne Street, Cambridge, MA 02139
- Founded: 2018
- Employees: 200+
- Category: Biotech
Investment
Verve Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series C
- GV: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- ARCH Venture Partners: Verified investor in Series C
- Biomatics Capital: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...